Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 CatalystsSeeking Alpha • 08/13/25
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/07/25
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 06/04/25
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/08/25
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 05/08/25
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025GlobeNewsWire • 04/23/25
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of DirectorsGlobeNewsWire • 04/09/25
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsSeeking Alpha • 03/28/25
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/25/25
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell LymphomaGlobeNewsWire • 03/20/25
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/19/25
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025GlobeNewsWire • 03/17/25
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)GlobeNewsWire • 03/12/25
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/04/25
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 01/13/25
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/25